Patents by Inventor Stephen Edward Rapecki

Stephen Edward Rapecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210140972
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 13, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, David James MCMILLAN, Graham John WARRELLOW, Daniel Christopher BROOKINGS, Rikki Peter ALEXANDER
  • Publication number: 20210088530
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 25, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Patent number: 10883996
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: January 5, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, David James McMillan, Graham John Warrellow, Daniel Christopher Brookings, Rikki Peter Alexander
  • Publication number: 20200400678
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Application
    Filed: May 26, 2020
    Publication date: December 24, 2020
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW
  • Patent number: 10829566
    Abstract: The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventor: Stephen Edward Rapecki
  • Patent number: 10775385
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Wootton
  • Patent number: 10774152
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10730952
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10705094
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: July 7, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
  • Publication number: 20200157215
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 21, 2020
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Patent number: 10618957
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 14, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Patent number: 10590197
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 17, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Publication number: 20200024346
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 23, 2020
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Michael John WRIGHT, Kerry Louise TYSON
  • Publication number: 20190359713
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 28, 2019
    Inventors: HELENE MARGARET FINNEY, STEPHEN EDWARD RAPECKI, MICHAEL JOHN WRIGHT, KERRY LOUISE TYSON
  • Publication number: 20190322739
    Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 24, 2019
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Michael John WRIGHT
  • Patent number: 10370447
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 6, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10358493
    Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 23, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright
  • Patent number: 10308723
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 4, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Publication number: 20190144945
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 16, 2019
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, John Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
  • Patent number: 10208349
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt